Resmed Inc’s filing revealed that its Officer Farrell Michael J. acquired Company’s shares for reported $2.23 million on Sep 08 ’25. In the deal valued at $278.14 per share,8,009 shares were bought.
Then, Sandercock Brett sold 3,000 shares, generating $812,310 in total proceeds. Upon selling the shares at $270.77, the Chief Financial Officer now owns 87,745 shares.
Before that, Sandercock Brett bought 3,000 shares. Resmed Inc shares valued at $812,310 were divested by the Officer at a price of $270.77 per share.
CLSA upgraded its Resmed Inc [RMD] rating to an Outperform from a a Hold in a research note published recently. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who increased its forecast for the stock in mid July from “a Sector perform” to “an Outperform”. Morgan Stanley began covering RMD with “an Overweight” recommendation on March 19, 2025. Morgan Stanley started covering the stock on March 19, 2025. It rated RMD as “an Overweight”.
Price Performance Review of RMD
On Monday, Resmed Inc [NYSE:RMD] saw its stock jump 0.87% to $279.46. Over the last five days, the stock has gained 1.80%. Resmed Inc shares have risen nearly 14.18% since the year began. Nevertheless, the stocks have risen 22.20% over the past one year. While a 52-week high of $293.81 was reached on 08/22/25, a 52-week low of $199.92 was recorded on 04/07/25.
Levels Of Support And Resistance For RMD Stock
The 24-hour chart illustrates a support level at 275.31, which if violated will result in even more drops to 271.16. On the upside, there is a resistance level at 281.67. A further resistance level may holdings at 283.88.
How much short interest is there in Resmed Inc?
A steep rise in short interest was recorded in Resmed Inc stocks on 2025-08-15, dropping by -0.44 million shares to a total of 8.94 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-15 was 9.38 million shares. There was a decline of -4.92%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 16, 2025 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating.
